No patent or exclusivity listings for this strength.
#002 — EQ 5MG BASE;10MG
AB
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Feb 5, 2010
#003 — EQ 5MG BASE;20MG
AB
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Feb 5, 2010
#004 — EQ 10MG BASE;20MG
AB
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Feb 5, 2010
#005 — EQ 5MG BASE;40MG
AB
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Jul 5, 2011
#006 — EQ 10MG BASE;40MG
AB
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Jul 5, 2011
Change History (1)
Recent changes detected for this application.
MODIFIEDrs7/1/2026
Lupin Pharmaceuticals' AMLODIPINE BESYLATE and BENAZEPRIL HYDROCHLORIDE product (NDA 078466, supplement 006) was designated as a reference-listed drug (RLD).